perlecan

amino acid sequence and structural model given in first source

Also Known As:

HSPG2 protein, human; Hspg2 protein, mouse; Hspg2 protein, rat; endorepellin protein, human; heparan sulfate proteoglycan 2; heparan sulfate proteoglycan 2 (perlecan) protein, human; heparan sulfate proteoglycan 2 protein, rat; perlecan (heparan sulfate proteoglycan 2) protein, mouse

Networked: 331 relevant articles (5 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Farach-Carson, Mary C: 14 articles (03/2021 - 01/2005)
2.	Bix, Gregory J: 13 articles (01/2022 - 08/2011)
3.	Arikawa-Hirasawa, Eri: 12 articles (01/2022 - 05/2002)
4.	Whitelock, John M: 11 articles (09/2020 - 02/2004)
5.	Saku, Takashi: 11 articles (05/2016 - 08/2002)
6.	Melrose, James: 10 articles (05/2022 - 04/2002)
7.	Iozzo, Renato V: 10 articles (01/2017 - 10/2003)
8.	Cheng, Jun: 9 articles (05/2016 - 02/2004)
9.	Maruyama, Satoshi: 7 articles (05/2016 - 05/2008)
10.	Yamazaki, Manabu: 7 articles (05/2016 - 03/2004)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2019 - "Perlecan-targeted nanoparticles showed improved cell uptake, retention, cytotoxicity in vitro and enhanced tumor growth inhibition in vivo. " 01/01/2006 - "Additional co-localization studies suggest that other tumor types may also have a Perlecan-modulated hedgehog signaling pathway. " 07/19/2022 - "Heparan sulfate proteoglycan 2 (HSPG2) frequently mutates in both tumors. " 01/01/2020 - "Depending on its state in the TME, perlecan can either prevent or promote the progression of cancers to metastatic disease. " 07/01/2019 - "The data presented here indicates that perlecan-targeted nanoparticles can improve tumor drug delivery to TNBC."
2.	Stroke (Strokes) 10/01/2013 - "Perlecan domain V is neuroprotective and affords functional improvement in a photothrombotic stroke model in young and aged mice." 01/01/2021 - "As neurogenesis is an important component of chronic post-stroke repair, and previous studies have implicated perlecan in developmental neurogenesis, we hypothesized that domain V could have a broad therapeutic window by enhancing neurogenesis after stroke. " 01/01/2021 - "Furthermore, perlecan deficient mice had significantly less neuroblast precursor cells after experimental stroke. " 01/01/2021 - "The extracellular matrix fragment perlecan domain V is neuroprotective and functionally restorative following experimental stroke. " 01/01/2021 - "Perlecan Domain-V Enhances Neurogenic Brain Repair After Stroke in Mice."
3.	Ischemic Stroke 12/01/2023 - "Recombinant Human Perlecan DV and Its LG3 Subdomain Are Neuroprotective and Acutely Functionally Restorative in Severe Experimental Ischemic Stroke." 01/01/2023 - "In addition, analysis of experimental data revealed promising insight into the potential uses of perlecan domain V as a broad treatment for ischemic stroke and AD. " 01/01/2023 - "We also examined the therapeutic potential of perlecan signaling in ischemic stroke, AD, and osteoarthritic animal models. " 01/01/2022 - "Perlecan domain V promotes reconstitution of the blood brain barrier damaged by ischemic stroke and is neurogenic and neuroprotective. " 08/01/2011 - "Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents."
4.	Infarction (Infarctions) 06/01/2000 - "Immunostaining for bFGF was localized surrounding the infarct granulation tissue on day 7 and overlapped with perlecan immunostaining. " 06/01/2000 - "Immunopositive staining for perlecan was observed in the infarct zone around granulation tissue on day 7 and in the entire infarct zone on days 14-28. " 10/07/2019 - "Using a transient middle cerebral artery occlusion model, we found larger infarct volumes and more BBB leakage in conditional perlecan (Hspg2)-deficient (Hspg2 - / - -TG) mice than in control mice. " 07/10/2007 - "In the bFGF + MI group, the +dp/dt and -dp/dt were improved markedly, the infarct size was significantly smaller, the MVD value was higher than those of the MI group on day 14 and day 28; the perlecan mRNA expression was higher in the infarct marginal area and interior zone; and the expression of FAK and the p38MAPK phosphorylation were up-regulated in the marginal zone of the bFGF group. " 06/01/2000 - "In situ hybridization revealed mRNA signals for perlecan in the infarct marginal zone on day 2 and in the infarct interior zone around infarct granulation tissue on day 7. On day 14 the signals were observed at the center point of the infarct. "
5.	Albuminuria 11/01/2001 - "Decreased perlecan in the glomerular basement membrane has a central role in the development of diabetic albuminuria. " 01/01/2013 - "Sulodexide treatment significantly reduced albuminuria, improved renal function, increased glomerular perlecan expression and reduced collagen type I and IV expression and ERK activation. " 01/01/2013 - "Mice with DN showed progressive albuminuria and renal deterioration over time, accompanied by mesangial expansion, PKC and ERK activation, increased renal expression of TGF-β1, fibronectin and collagen type I, III and IV, but decreased glomerular perlecan expression. " 09/01/1994 - "At 12 months albuminuria, renal collagen IV and perlecan mRNA levels, anionic and neutral dextran clearances, glomerular basement membrane morphometry, and mesangial cell proliferation were evaluated. " 02/01/2007 - "In summary, the differential effects of PKC-beta deficiency on diabetes-induced renal hypertrophy and albuminuria suggest that PKC-beta contributes to high-glucose-induced TGF-beta1 expression and renal fibrosis, whereas perlecan, as well as nephrin, expression and albuminuria is regulated by other signaling pathways."

Related Drugs and Biologics

1.	Messenger RNA (mRNA)
2.	Collagen Type I (Type I Collagen)
3.	glucuronyl glucosamine glycan sulfate (sulodexide)
4.	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)
5.	Proteins (Proteins, Gene)
6.	Collagen
7.	Proteoglycans (Proteoglycan)
8.	Fibronectins (Fibronectin)
9.	Versicans (Versican)
10.	Laminin (Merosin)

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Drug Therapy (Chemotherapy)
4.	Denervation
5.	Catheters